MeiraGTx

MeiraGTx is a clinical-stage genetic medicine company with a broad pipeline of late-stage programs supported by end-to-end manufacturing capabilities. The company focuses on viral vector design, optimization, and a transformative riboswitch gene regulation platform that enables precise, dose-responsive control of gene expression through oral small molecules. MeiraGTx targets metabolic peptides for diseases like diabetes and autoimmune conditions, expanding genetic medicine applications to common ailments while addressing unmet needs in large disease areas.